Home Cart Sign in  
Chemical Structure| 141430-65-1 Chemical Structure| 141430-65-1

Structure of ABT-751
CAS No.: 141430-65-1

Chemical Structure| 141430-65-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ABT-751 can inhibit microtubule polymerization through binding to β-tubulin on the colchine site.

Synonyms: E7010

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Hopkins, Megan D. ; Abebe, Felagot A. ; Scott, Kristina A. ; Ozmer, Garett L. ; Sheir, Alec A. ; Schroeder, Lucas J. , et al.

Abstract: Sulfonamides are a crucial class of bioisosteres that are prevalent in a wide range of pharmaceuticals, however, the available methods for their production directly from heteroaryl aldehyde reagents remains surprisingly limited. A new approach for regioselective incorporation of a sulfonamide unit to heteroarene scaffolds has been developed and is reported within. As a result, a variety of primary benzylic N-alkylsulfonamides have been prepared via a two-step (one pot) formation from the in situ reduction of an intermediate N-sulfonyl imine under mild, practical conditions. The compounds have been screened against a variety of cell lines for cytotoxicity effects using a Cell Titer Blue assay. The cell viability investigation identifies a subset of N-benzylic sulfonamides derived from the indole scaffold to be targeted for further development into novel molecules with potential therapeutic value. The most cytotoxic of the compounds prepared, AAL-030, exhibited higher potency than other well-known anticancer agents Indisulam and ABT-751.

Purchased from AmBeed:

Alternative Products

Product Details of ABT-751

CAS No. :141430-65-1
Formula : C18H17N3O4S
M.W : 371.41
SMILES Code : O=S(C1=CC=C(C=C1)OC)(NC2=CC=CN=C2NC3=CC=C(C=C3)O)=O
Synonyms :
E7010
MDL No. :MFCD00910291
InChI Key :URCVCIZFVQDVPM-UHFFFAOYSA-N
Pubchem ID :3035714

Safety of ABT-751

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ABT-751

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SK-Mel-2 262.2 nM 5 days Evaluate the anti-proliferative effect of ABT-751 in melanoma cell lines, IC50 value was 262.2 nM. PMC11043045
WM-266-4 298.9 nM 5 days Evaluate the anti-proliferative effect of ABT-751 in melanoma cell lines, IC50 value was 298.9 nM. PMC11043045
WM-115 208.2 nM 5 days Evaluate the anti-proliferative effect of ABT-751 in melanoma cell lines, IC50 value was 208.2 nM. PMC11043045
Sk-Mel-28 697.9 nM 5 days Evaluate the anti-proliferative effect of ABT-751 in melanoma cell lines, IC50 value was 697.9 nM. PMC11043045
Sk-Mel-5 259.7 nM 5 days Evaluate the anti-proliferative effect of ABT-751 in melanoma cell lines, IC50 value was 259.7 nM. PMC11043045
Malme-3M 465.2 nM 5 days Evaluate the anti-proliferative effect of ABT-751 in melanoma cell lines, IC50 value was 465.2 nM. PMC11043045
Lox-IMVI 1007.2 nM 5 days Evaluate the anti-proliferative effect of ABT-751 in melanoma cell lines, IC50 value was 1007.2 nM. PMC11043045
J82 0.7 μM 24 hours ABT-751 induced G2/M cell cycle arrest, decreased cell number in the S phase of the cell cycle and suppressed colony formation/independent cell growth, accompanied with alterations of the protein levels of several cell cycle regulators. PMC7835924
BFTC905 0.6 μM 24 hours ABT-751 induced G2/M cell cycle arrest, decreased cell number in the S phase of the cell cycle and suppressed colony formation/independent cell growth, accompanied with alterations of the protein levels of several cell cycle regulators. PMC7835924
GBM CD105+ cells 0.5 μM and 10 μM 48 hours and 96 hours Screening for effective drugs against GBM CD105+ cells, ABT-751 showed robust toxic effects on GBM CD105+ cells. PMC9426031
Lung cancer A549 cell 4.58 μM 72 hours Evaluate the growth inhibitory activity of ABT-751 against A549 cells, with a GI50 value of 4.58 μM. PMC6359563
Breast cancer MCF-7 cell 0.88 μM 72 hours Evaluate the growth inhibitory activity of ABT-751 against MCF-7 cells, with a GI50 value of 0.88 μM. PMC6359563
Leukemia K562 cell 0.74 μM 72 hours Evaluate the growth inhibitory activity of ABT-751 against K562 cells, with a GI50 value of 0.74 μM. PMC6359563
MCF-7 CC cells 10μM 24 hours To evaluate the effects of ABT-751 on microtubule formation, results showed that MCF-7 CC cells were less sensitive to ABT-751, with microtubule fibers not completely disappearing at 10μM. PMC5546696
MCF-7 TXT cells 10μM 24 hours To evaluate the effects of ABT-751 on microtubule formation, results showed that MCF-7 TXT cells were more sensitive to ABT-751, with microtubule fibers completely disappearing at 10μM. PMC5546696

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00047489 Hematological Malignancies PHASE1 COMPLETED 2025-01-05 The University of Texas M.D. A... More >>nderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00063102 Breast Cancer PHASE2 COMPLETED 2025-08-04 Oncology-Hematology Group of S... More >>outh Florida, Miami, Florida, 33176, United States|Clinical Research Network, Inc., Plantation, Florida, 33324, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Northwestern University Medical School Division of Hematology/Oncology, Chicago, Illinois, 60611, United States|Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion, Indianapolis, Indiana, 46202, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Oncology & Hemotology Associates of Kansas City, PA, Kansas City, Missouri, 64111, United States|Texas Oncology, Dallas, Texas, United States Less <<
NCT00073151 Non-Small Cell Lung Cancer PHASE2 COMPLETED 2025-01-06 Oncology Hematology Group of S... More >>outh Florida, Miami, Florida, United States|Florida Cancer Institute, New Port Richey, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, 60637-1460, United States|University of Maryland Greenbaum Cancer Center, Baltimore, Maryland, 21201-1595, United States|Oncology & Hematology Associates of Kansas City, PA, Kansas City, Missouri, 64111, United States|Washington University School of Medicine, St. Louis, Missouri, 63110-1093, United States|Albany Regional Cancer Center, Albany, New York, United States|Raleigh Hematology Oncology, Cary, North Carolina, United States|Dayton Oncology and Hematology, Kettering, Ohio, United States|Cancer Care Associates, Oklahoma City, Oklahoma, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|West Cancer Clinic, Memphis, Tennessee, 38120, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, Ft. Worth, Texas, United States|Cancer Care Northwest, Spokane, Washington, United States|Northwest Cancer Specialists, Vancouver, Washington, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, 53792-5666, United States Less <<
NCT00471718 Prostate Cancer PHASE1|PHASE2 TERMINATED 2025-08-09 Vanderbilt-Ingram Cancer Cente... More >>r, Nashville, Tennessee, 37232-6838, United States Less <<
NCT00073138 Colorectal Cancer PHASE2 COMPLETED 2025-02-05 University of Southern Califor... More >>nia, Los Angeles, California, 90089, United States|Cancer Institute Medical Group, Santa Monica, California, 90095-3961, United States|Northwestern University, Chicago, Illinois, 60611-5933, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|University of Wisconsin Medical Center, Madison, Wisconsin, 53792, United States Less <<
NCT00036959 Brain and Central Nervous Syst... More >>em Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific Less << PHASE1 COMPLETED 2025-02-10 Children's Memorial Hospital -... More >> Chicago, Chicago, Illinois, 60614, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, 20892-1182, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104-4318, United States Less <<
NCT00073112 Renal Cell Cancer PHASE2 COMPLETED 2025-09-06 Arizona Cancer Research Center... More >>, Tucson, Arizona, 85712, United States|UCLA School of Medicine, Los Angeles, California, 90024, United States|Clinical Trials + Research Associates, Montebello, California, 90640, United States|US Oncology Inc Rocky Mountain Cancer Centers, Denver, Colorado, 80218, United States|Oncology Hematology Group of South Florida, Miami, Florida, United States|US Oncology Inc Florida Cancer Institute, New Port Richey, Florida, 34652, United States|US Oncology Inc Ocala Oncology Center, Ocala, Florida, 34474, United States|US Oncology Inc Cancer Centers of Florida, P.A., Orlando, Florida, 32806, United States|University of Chicago Medical Center, Chicago, Illinois, 60637-1471, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21231, United States|US Oncology Inc Raleigh Hematology Oncology Clinic, Cary, North Carolina, 27511, United States|US Oncology Inc Dayton Oncology & Hematology P.A., Kettering, Ohio, 45409, United States|US Oncology Inc Cancer Care Accociates-Mercy Campus, Oklahoma City, Oklahoma, 73120, United States|US Oncology Inc Cancer Centers of the Carolinas, Greenville, South Carolina, 29615, United States|West Cancer Clinic, Memphis, Tennessee, 38120, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37232-6307, United States|US Oncology Inc Tyler Cancer Center, Tyler, Texas, 75702, United States|US Oncology Inc Cancer Care Northwest-North, Spokane, Washington, 99218, United States|US Oncology Inc Northwest Cancer Specialists, Vancouver, Washington, 98684, United States|B.C. Vancouver Cancer Agency, Vancouver, British Columbia, V5Z 4E6CAN, Canada|Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, B3H2Y9, Canada|McMaster University, Hamilton, Ontario, L8N 4A6, Canada|McGill University, Montreal, Quebec, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.46mL

2.69mL

1.35mL

26.92mL

5.38mL

2.69mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories